Skip to main content
SpringerLink
Log in

Stellenwert der Tumormarker bei der Früherkennung gastrointestinaler Tumoren

  • Conference paper
94. Kongreß

Part of the book series: Verhandlungen der Deutschen Gesellschaft für Innere Medizin ((VDGINNERE,volume 94))

  • 27 Accesses

Zusammenfassung

Die Entwicklung der Hybridomtechnologie [27] erweckte vielfach die Hoffnung, über die Gewinnung sogenannter monoklonaler Antikörper (MAK) die Frühdiagnostik gastrointestinaler Karzinome entscheidend verbessern zu können: über die Verbesserung „alter“Testsysteme, z.B. durch Einführung von MAK gegen das CEA oder AFP, und über die Entdeckung neuer tumorassoziierter Antigene (TAA).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arps H, Dietel M, Klapdor R, Kremer B (1986) Immunohistologically determined expression of the tumorassociated antigens CA 19–9, CA 125, 17–1A and CA 50 in tumors of the gastro-intestinal tract. In: Greten H, Klapdor R (eds) Clinical relevance of new monoclonal antibodies, 3. Symposium on tumor markers, Hamburg 1985. Thieme, Stuttgart New York, pp 276–284

    Google Scholar 

  2. Bast RC, Klug THL, John ST, Jenison E (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883–886

    Article  PubMed  Google Scholar 

  3. Baum RP, Maul FD, Klapdor R, Senekowitsch R, Lorenz M, Hottenrott C, Montz R, Happ J, Kriegel H, Chatal JF, Hör G (1985) Immunszintigraphie colorektaler Tumoren mit J-131-markierten monoklonalen Antikörpern (19–9/anti-CEA): Erste Ergebnisse. Nuc Compact 16:121–128

    Google Scholar 

  4. Chatal JF, Saccavini JC, Fumoleau P, Douillard JC, Curtet CH, Kremer M, Le Mevel B, Koprowski H (1984) Immunscintigraphy of colon carcinoma. J Nucl Med 25:307–314

    PubMed  CAS  Google Scholar 

  5. Colcher D, Horan Hand P, Nuti P, Schlom JA (1981) Spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 78:3199–3203

    Article  PubMed  CAS  Google Scholar 

  6. Dallek M, Klapdor R, Helling K, van Ackeren H, Kranz HW (1986) Diagnosis of recurrence and follow-up of cancers in the large intestine using CEA and the new „tumor markers“ CA 19–9 and CA 125. In: Greten H, Klapdor R (eds) Clinical relevance of new monoclonal antibodies, 3.Symposium on tumor markers, Hamburg 1985. Thieme, Stuttgart New York, pp 38–44

    Google Scholar 

  7. Del Villano BD, Brennan S, Brock P, Boucher C, Liu V (1983) Radiomimmunometric assay for a monoclonal antibody defined tumor marker CA 19–9. Clin Chem 29:549–553

    PubMed  Google Scholar 

  8. Fossei ET, Carr JM, McDonagh J (1986) Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. N Engl J Med 315:1369–1376

    Article  Google Scholar 

  9. Gronowitz JS, Källander CFR, Hagberg H, Diderholm H, Pettersson U (1984) Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer 33:5–11

    Article  PubMed  CAS  Google Scholar 

  10. Haglund C, Kuusela P, Jalanko H, Roberts PJ (1987) Serum Ca 50 as a tumor marker in pancreatic cancer: a comparison with CA 19–9. Int J Cancer 39:477–481

    Article  PubMed  CAS  Google Scholar 

  11. Helfrich G, Klapdor U, Bahlo M, Klapdor R, Schreiber HW (1987) Determination of the tumor markers CA 19–9, Ca 125, CA 15–3, CA 50 and CEA in acute and chronic benign diseases in medical/surgical patients. In: Klapdor R (ed) New tumor markers and their monoclonal antibodies — actual clinical relevance for diagnosis and therapy of solid tumors, 4. Symposium on tumor markers, Hamburg 1986. Thieme, Stuttgart New York, pp 287–290

    Google Scholar 

  12. Herlyn MF, Koprowski H (1980) Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 40:717–721

    PubMed  CAS  Google Scholar 

  13. Holmgren J, Lindholm L, Persson B, Lagergard T, Nilson O, Svennerholm L, Rudenstam CM, Unsgaard B, Yngvason F, Pettersson S, Killander AF (1984) Detection by monoclonal antibody of carbohydrate antigen CA 50 in serum of patients with carcinoma. Br Med J 288:1479–1482

    Article  CAS  Google Scholar 

  14. Holstege A, Pauff M, Kirchner R, Gerok W (1987) Increased urinary excretion of modified nucleosides in cases of colorectal carcinoma: comparison with CEA and correlation to tumor progression. In: Klapdor R (ed) New tumor markers and their monoclonal antibodies — acutal clinical relevance for diagnosis and therapy of solid tumors, 4. Symposium on tumor markers, Hamburg 1986. Thieme, Stuttgart New York, pp 265–269

    Google Scholar 

  15. Kato H, Tamai K, Morioka M, Nagai T, Nagaya T, Torigoe T (1984) Tumor-antigen TA 4 in the detection of recurrence in cervical squamous cell carcinoma. Cancer 54:1544–1560

    Article  PubMed  CAS  Google Scholar 

  16. Klapdor R, Lehmann U, Bahlo M, Greten H, van Ackeren H, Dallek M, Schreiber HW (1983) CA 19–9 in der Diagnostik und Differentialdiagnostik des exkretorischen Pankreaskarzinoms. Tumor Diagn Ther 4:197–201

    Google Scholar 

  17. Klapdor R, Greten H (1984) Das tumor-assoziiierte Antigen CA 19–9 in der Differentialdiagnostik und Verlaufskontrolle von Malignomen des Pankreas und Magen-Darm-Traktes. Dtsch Med Wochenschr 109:1935–1937

    Article  PubMed  CAS  Google Scholar 

  18. Klapdor R, Klapdor U, Bahlo M, Dallek M, Kremer B, van Ackeren H, Schreiber HW, Greten H (1984) CA 125 bei Karzinomen des Verdauungstraktes — Ein Vergleich mit CA 19–9 und CEA bei Karzinomen des Pankreas und Colon. Dtsch Med Wochenschr 109:1949–1952

    Article  PubMed  CAS  Google Scholar 

  19. Klapdor R, Klapdor U, Bahlo M, Greten H (1984) CA 19–9 in der Diagnostik und Differentialdiagnostik des exkretorischen Pankreaskarzinoms, 2. Mitteilung. Tumor Diagn Ther 5:161–165

    Google Scholar 

  20. Klapdor R, Klapdor U, Montz R, Dietel M, Arps H, Schreiber HW, Greten H (1987) New tumor associated antigens and their monoclonal antibodies in the follow up of exocrine pancreatic carcinoma. In: Klapdor R (ed) New tumor markers and their monoclonal antibodies — actual clinical relevance for diagnosis and therapy of solid tumors, 4. Symposium on tumor markers, Hamburg 1986. Thieme, Stuttgart New York, pp 154–166

    Google Scholar 

  21. Klapdor R, Bahlo M, Schwarzenberg O, Riethmüller G (1987) Immunotherapy of exocrine pancreatic carcinoma xenografts in nude mice by the monoclonal antibody 17–1A. Blut 55:361–364

    Google Scholar 

  22. Klapdor R, Montz R (1988) Clinical and Immunological response to the therapy of pancreatic cancer with murine monoclonal antibodies. In: Epenetos AA, Oberhausen E, Reisfeld RA (eds) Immunotherapy and -scintigraphy of tumors with monoclonal antibodies. Zuckschwerdt, München Bern Wien San Francisco, pp 87–95

    Google Scholar 

  23. Klapdor R, Harms F, Bahlo M, Arps H, Dietel M (1988) Tumor marker secretion (CA 19–9, CEA, CA 125) by xenografts of 8 different human pancreatic carcinomas compared to the human tumors (in press)

    Google Scholar 

  24. Klapdor U, Klapdor R, Montz R, Greten H (1985) Neue Tumormarker für die Diagnose und Verlaufskontrolle maligner Tumoren. In: Klapdor R, Schildberg FW, Wawersik J (Hrsg) Ernährung in Klinik und Praxis — Aktuelles aus Onkologie und Chirurgie. Zuckschwerdt, München Bern Wien, S 1–18

    Google Scholar 

  25. Klapdor U, Bahlo M, Klapdor R, Franke N, Hirschmann M (1988) Effects of cytotoxic drugs on tumor marker secretion of g.i. and pancreatic carcinomas — comparison of studies in nude mice and in patients (in press)

    Google Scholar 

  26. von Kleist S (1983) Das carcinoembryonale Antigen (CEA) — Biologische Grundlagen und klinische Anwendung. Schattauer, Stuttgart New York, S 87

    Google Scholar 

  27. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specifity. Nature 265:495–501

    Article  Google Scholar 

  28. Koprowski H, Herlyn M, Steplewsi Z, Sears HF (1981) Specific antigen in serum of patients with colon carcinoma. Science 212:53–56

    Article  PubMed  CAS  Google Scholar 

  29. Lindholm L., Holmgren J, Svennerholm L, Fredman P, Nilsson O, Perrsson B, Myrvold H, Lagergard T (1983) Monoclonal antibodies against gastrointestinal tumor-associated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immunol 71:178–182

    Article  PubMed  CAS  Google Scholar 

  30. Metzgar RS, Gaillard MT, Levine SJ, Tuck FL, Bossen EH, Borowitz MJ (1982) Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. Cancer Res 42:601–608

    PubMed  CAS  Google Scholar 

  31. Montz R, Klapdor R, Rothe B, Heller M (1986) Immunoscintigraphy and radioimmunotherapy in patients with pancreatic carcinoma. Nucl Med 25:239–244

    CAS  Google Scholar 

  32. Nakano K, Shindo K, Yasaka T (1985) Reversed-phase highperfomance liquid chromatographic investigation of mucosal nucleosides and bases and urinary modified nucleosides of gastrointestinal cancer patients. J Chromatogr 343:21–33

    Article  PubMed  CAS  Google Scholar 

  33. Nishida K, Yoshikawa T, Fukumoto K, Kondo M (1986) Elevated pancreatic oncofetal antigen levels measured by enzyme immunoassay in pure pancreatic juice of patients with pancreatic cancer. Oncology 43:311–315

    Article  PubMed  CAS  Google Scholar 

  34. Tempero MA, Pour PM, Uchida E, Herlyn D, Zeplewski Z (1986) Monoclonal antibody CO 17–1A and leukopheresis in immunotherapy of pancreatic cancer. Hybridoma 5:133–138

    Google Scholar 

  35. Schmiegel WH, Eberl W, Kreiker C, Kalthoff H, Bützow GH, Jessen K, Klapdor R, Soehendra N, Wargenau M, Classen M, Greten H, Thiele HG (1985) Multiparametric tumor marker (CA 19–9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases. Hepatogastroenterology 31:141–145

    Google Scholar 

  36. Sears HF, Atkinson B, Mattis J, Herlyn D (1982) Phase-I-clinical trial of monoclonal antibody in treatment of gastrointestinal tumors. Lancet I:762–765

    Google Scholar 

  37. Staab HJ, Glock S, Hornung A (1982) Ein neuer Festphasen-Enzymoimmunotest mit monoklonalem Antikörper zur CEA Bestimmung bei Patienten mit verschiedenen Karzinomen. Tumor Diagn Therapie 4/5:183–194

    Google Scholar 

  38. Staab HJ (1984) Medizinisch-biologische Bedeutung des Carcinoembryonalen Antigens (CEA): Klinische Studien und experimentelle Modelle. Editiones Roche, Basel, S 146

    Google Scholar 

  39. Staab HJ, Hornung A, Anderer FA, Kieninger G (1984) Klinische Bedeutung des zirkulierenden tumorassoziierten Antigens CA 19–9 bei Karzinomen des Verdauungstraktes. Dtsch Med Wochenschr 109:1141–1147

    Article  PubMed  CAS  Google Scholar 

  40. Tatsatu M, Yamamura H, Iishi H, Ichii M, Noguchi S, Yamamoto R, Okuda S (1985) Values of CA 19–9 in the serum, pure pancreatic juice and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor. Cancer 56:2669–2673

    Article  Google Scholar 

  41. UICC (1987) TNM Klassifikation maligner Tumoren, 4. Auflage, Springer, Berlin Heidelberg New York Tokyo, S213

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. I. Medizinische Klinik, Universitätskrankenhaus Eppendorf, Hamburg, Deutschland

    R. Klapdor

Authors
  1. R. Klapdor
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Humboldtstr. 14, D-6200, Wiesbaden, Deutschland

    Klaus Miehlke

Rights and permissions

Reprints and permissions

Copyright information

© 1988 J. F. Bergmann Verlag, München

About this paper

Cite this paper

Klapdor, R. (1988). Stellenwert der Tumormarker bei der Früherkennung gastrointestinaler Tumoren. In: Miehlke, K. (eds) 94. Kongreß. Verhandlungen der Deutschen Gesellschaft für Innere Medizin, vol 94. J.F. Bergmann-Verlag. https://doi.org/10.1007/978-3-642-85461-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85461-3_6

  • Publisher Name: J.F. Bergmann-Verlag

  • Print ISBN: 978-3-8070-0376-4

  • Online ISBN: 978-3-642-85461-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation